Theravance Biopharma (TBPH) Misses Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Theravance Biopharma, Inc. Reports First Quarter 2016 Financial Results and Provides Business Update
May 9, 2016 4:15 PM EDTDUBLIN, IRELAND -- (Marketwired) -- 05/09/16 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported financial results for the first quarter ended March 31, 2016. Revenue for the first quarter 2016 was $18.4 million. The first quarter operating loss excluding share-based compensation was $30.3 million, or $41.6 million including share-based compensation of $11.3 million. Cash, cash equivalents, and marketable securities totaled $214.5 million as of March 31, 2016. The quarter-end cash balance excludes $37.5 million in receivables from collaborative arrangements and approximately $107.7 million in net proceeds from the Company's recent public offering of its ordinary shares.
Rick E Winningham, Chairman and... More
